Bivalent RSVpreF Subunit Vaccine Safety and Immunogenicity in Seropositive 2–<18 Year Olds

<b>Background/Objectives:</b> We aimed to determine safe and immunogenic RSVpreF vaccine dose levels for further clinical development in 2–<18 year olds. <b>Methods:</b> The phase 1, age-descending, open-label Picasso trial evaluated different RSVpreF dose levels in respiratory syncytial virus (RSV)...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Julia Glanternik, Grant C. Paulsen, Shelly Senders, Michael Smith, Emma Shittu, Barbara A. Pahud, Lisa Pereira, Lesong Chen, Maria Maddalena Lino, Elena V. Kalinina, Danielle Baranova, Warren V. Kalina, Elie Needle, MaryAnn Murillo, John M. Leech, David Cooper, Kena A. Swanson, Annaliesa S. Anderson, Alejandra Gurtman, Iona Munjal
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2026-01-01
Edice:	Vaccines
Témata:	clinical trial immunogenicity pediatric LRTI RSV RSVpreF
On-line přístup:	https://www.mdpi.com/2076-393X/14/2/128
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!